Digital and Manual Assessment of Intrafollicular Ki-67, MYC, and p53 in Classic Follicular Lymphoma.

George C de Castro¹, Morgan L Shannon², Ruth Zhang³, Kunwar Singh⁴, Robert S Ohgami⁵, Kwun Wah Wen¹

¹Department of Pathology, University of California San Francisco, San Francisco, CA 94143, USA.

²Department of Internal Medicine, Stanford Health Care, Palo Alto, CA 94305, USA.

³Peninsula Pathologists Medical Group, South San Francisco, CA 94063, USA.

⁴Guardant Health, Redwood City, CA 94063, USA.

⁵Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT 84108, USA.

PubMed PMC DOI PDF

Abstract

Background/Objectives: There remains a need for additional prognostic markers in classic follicular lymphoma (cFL) to identify aggressive disease. Immunohistochemical stains such as Ki-67, MYC, and p53 have shown variable associations with histologic grade and adverse outcomes. In this study, we aimed to assess intrafollicular Ki-67, MYC, and p53 expression in cFL via immunohistochemistry, quantif…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.